Advertisement
Royalty Pharma plc

Royalty Pharma plc (RPRX) Stock Overview

Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

RPRX●NASDAQ
HealthcareBiotechnology
$55.02
$0.05(0.09%)
U.S. Market opens in 16h 8m
Advertisement

Royalty Pharma plc (RPRX)

Meyka AI Score

Z

Key Financials

Market Cap23.7B
P/E Ratio28.79
EPS (TTM)$1.90
ROE0.13%
Fundamental Analysis

AI Price Forecasts

1 Month$47.41
3 Months$47.21
1 Year Target$50.45

RPRX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Royalty Pharma plc (RPRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 64.39, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $50.45.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 28.79 and a market capitalization of 23.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.09%
5-Day Change
0.99%
1-Month Change
9.60%
3-Month Change
16.003%
6-Month Change
40.54%
Year-to-Date (YTD) Change
42.39%
1-Year Change
64.53%
3-Year Change
65.18%
5-Year Change
21.70%
All-Time (Max) Change
23.64%

Contact Information

https://www.royaltypharma.com
212 883 0200
110 East 59th Street, New York City, NY, 10022

Company Facts

75 Employees
IPO DateJun 16, 2020
CountryUS
Actively Trading

Frequently Asked Questions